Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €13.51 EUR
Change Today -0.171 / -1.25%
Volume 0.0
I3F On Other Exchanges
As of 3:00 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (I3F) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €15.67
52 Week Low
05/9/14 - €6.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

infinity pharmaceuticals inc (I3F) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (I3F) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; DYNAMO+R that is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in combination with rituximab, a monoclonal antibody treatment; and DUO, which is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). It is also conducting a Phase Ib trial of IPI-145 in combination with obinutuzumab, a monoclonal antibody treatment in CLL patients; a Phase Ib/II clinical study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; and an ongoing Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

195 Employees
Last Reported Date: 02/24/15

infinity pharmaceuticals inc (I3F) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (I3F) Key Developments

Infinity Reports Preclinical Data for Duvelisib in Combination with Venetoclax

Infinity Pharmaceuticals, Inc. announced the presentation of new preclinical and translational data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase [3] (PI3K)-delta and PI3K-gamma, in combination with venetoclax (ABT-199), an investigational inhibitor of the BCL-2 protein, at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania. Preclinical data presented suggest that duvelisib treatment increased the sensitivity of tumor cells to venetoclax. These data provide a mechanistic rationale for evaluating duvelisib in combination with venetoclax in patients with hematologic malignancies, or blood cancers. New preclinical and translational data conducted in collaboration with researchers at MD Anderson Cancer Center were reported in a poster presentation, Elevated levels of BCL-2 during duvelisib (IPI-145) therapy: A mechanistic rationale for combining duvelisib and venetoclax (ABT-199) in chronic lymphocytic leukemia (CLL). Researchers evaluated gene and protein expression in samples from CLL patients in Infinity's Phase 1 study of duvelisib in patients with advanced hematologic malignancies. Duvelisib treatment enhanced the expression of certain factors that promote apoptosis and also enhanced the expression of BCL-2, a protein known to suppress apoptosis. Additionally, tumor samples from CLL patients treated with duvelisib for 28 days exhibited increased tumor cell apoptosis, or cell death, when treated with venetoclax ex vivo compared to pre-duvelisib therapy samples, suggesting that duvelisib sensitizes the tumor cells to BCL-2 inhibition.

Infinity Pharmaceuticals, Inc. Announces Executive Appointments

Infinity Pharmaceuticals, Inc. announced that Sujay Kango has joined the company as executive vice president, chief commercial officer and Winston K.C. Lam has joined as executive vice president, general counsel. Mr. Kango and Mr. Lam each bring more than 20 years of experience in the pharmaceutical industry, including expertise in oncology and hematology, and have played key roles in building successful companies and commercial organizations. Both Mr. Kango and Mr. Lam will report to Adelene Perkins, chair, president and chief executive officer at Infinity. Prior to joining Infinity, Mr. Kango most recently served as vice president, global marketing, sales operations (and business analytics) at Onyx Pharmaceuticals. Prior to joining Infinity, Mr. am served as executive vice president, business development and chief legal officer at Caris Life Sciences.

Infinity Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Twelve Months Ended December 31, 2014; Announces Update on duvelisib (IPI-145); Provides Earnings Guidance for the Full Year 2015

Infinity Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and twelve months ended December 31, 2014. For the quarter, the company reported loss from operations was $39,108,000 compared with $33,084,000 for the same period last year. Net loss was $40,343,000 or $0.83 basic and diluted per share compared with $32,925,000 or $0.68 basic and diluted per share for the same period last year. Collaboration revenue was $4,356,000. For the twelve months, the company reported loss from operations was $7,923,000 compared with $127,676,000 for the same period last year. Net loss was $17,416,000 or $0.36 basic and diluted per share compared with $126,780,000 or $2.64 basic and diluted per share for the same period last year. Revenue during 2014 was $165 million, which was composed of a onetime license fee of $159.1 million associated with the strategic collaboration with AbbVie and $5.9 million in R&D services. The company also announced ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity anticipates that it will report topline data from DYNAMOTM, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL), in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUOTM, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), in the second half of 2015. Additionally, Infinity anticipates that three company-sponsored clinical studies of duvelisib will be initiated in 2015, including the first clinical study of duvelisib in combination with venetoclax (ABT-199). For 2015, the company expects revenue to range from $105 million to $125 million based upon the anticipation of the $130 million milestone payment from AbbVie associated with the completion of enrollment for the first to occur of either DYNAMO or DUO. The company also expects net loss for 2015 to range from $190 million to $210 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I3F:GR €13.51 EUR -0.171

I3F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.43 USD +0.13
CTI BioPharma Corp $1.84 USD +0.02
Evotec AG €3.80 EUR -0.043
Exelixis Inc $3.15 USD +0.04
GlaxoSmithKline SAE £11.12 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation I3F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at